Biotech firm GlycoMimetics files S-1 for proposed IPO

Gaithersburg-based biotechnology firm GlycoMimetics “has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering of shares of its common stock,” according to a press release.
GlycoMimetics is focused on the “discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.”